ethyl 4-[4-(3-oxobutyl)phenoxy]butanoate | 174884-23-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: ethyl 4-[4-(3-oxobutyl)phenoxy]butanoate
• 英文别名: 4-[4-(3-Oxobutyl)phenoxy]butanoic acid, ethyl ester
• CAS: 174884-23-2
• 化学式: C₁₆H₂₂O₄
• 分子量: 278.348
• InChiKey: BXVCUAVSVABDQS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  20
• 可旋转键数：
  10
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  52.6
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  ethyl 4-[4-(3-oxobutyl)phenoxy]butanoate 在 potassium carbonate 作用下， 以 甲醇 、 水 为溶剂， 以385 mg (60%)的产率得到4-[4-(3-oxobutyl)phenoxy]butanoic acid
  参考文献：
  名称：

  Enediyne derivatives useful for the synthesis of conjugates of

  摘要：

  这项发明描述了从强效抗肿瘤抗生素calicheamicin家族的二硫化物类似物及其衍生物以及类似的来自于相关抗肿瘤抗生素esperamicin的类似物制备的载体-药物共轭物，载体可以是针对不需要的细胞群体（例如肿瘤细胞）的抗体、生长因子或类固醇。整个蛋白质载体以及它们的抗原识别片段和其化学或基因组操作的对应物都可用于共轭物的靶向部分。该发明包括合成这些共轭物所需的化合物、适当的药物组合物和它们的使用方法。

  公开号：

  US05739116A1
• 作为产物：
  描述：

  4-溴丁酸乙酯 、 覆盆子酮 在 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 ethyl 4-[4-(3-oxobutyl)phenoxy]butanoate
  参考文献：
  名称：

  用于迭代合成的羰基化合物的光诱导同系化

  摘要：

  描述了用于羰基同系化的光致 Büchner-Curtius-Schlotterbeck 型反应。该协议允许通过相应的 N-tosylhydrazone 阴离子的直接光激发，将羰基化合物用作安全且易于获得的重氮前体。以实用和迭代的方式制备功能化脂肪醛和酮。

  DOI：

  10.1002/anie.202211578

文献信息

• Phenethanolamine-derived haptens, immunogens, antibodies and conjugates
  申请人：McConnell Ivan Robert

  公开号：US20060223132A1

  公开（公告）日：2006-10-05

  The present invention relates to a method for preparing haptens of formulae I and II that are useful in the preparation of immunogens, antibodies and conjugates, for use in competitive immunoassays for the detection of ractopamine, isoxsuprine and ritodrine. The haptens are prepared by reacting a phenylethanolamine derivative of formula D with a phenylalkylcarbonyl derivative of formula E: in which, in formula I, Z 1 is a crosslinker and Z 2 is H and, in formula II, Z 1 is H and Z 2 is a crosslinker.

  本发明涉及一种制备公式I和II的半抗原的方法，该半抗原在制备免疫原、抗体和结合物中有用，用于竞争性免疫测定检测莱克多巴胺、异丝氨酮和利托腈。半抗原通过将公式D的苯乙醇胺衍生物与公式E的苯基烷基羧酰衍生物反应制备而成。在公式I中，Z1是交联剂，Z2是氢，在公式II中，Z1是氢，Z2是交联剂。
• Conjugates of methyltrithio antitumor agents and intermediates for their
  申请人：American Cyanamid Company

  公开号：US05773001A1

  公开（公告）日：1998-06-30

  This invention describes carrier-drug conjugates prepared from disulfide analogs of the calicheamicin family of potent antitumor antibiotics and their derivatives, as well as similar analogs from related antitumor antibiotics such as the esperamicins. The carrier can be an antibody, growth factor, or steroid which targets an undesired population of cells, such as those of a tumor. Whole protein carriers as well as their antigen-recognizing fragments and their chemically or genetically manipulated counterparts are useful for the targeting portion of the conjugates. This invention includes compounds required for the synthesis of these conjugates, appropriate pharmaceutical compositions of the carrier-drug conjugates, and their method of use.

  本发明描述了由卡利奇阿霉素家族的二硫化物类似物及其衍生物制备的载体-药物共轭物，以及来自相关抗肿瘤抗生素（如埃斯佩拉霉素）的类似物。载体可以是抗体、生长因子或类固醇，其靶向不需要的细胞群体，如肿瘤细胞。整个蛋白质载体以及其抗原识别片段和其化学或基因操作的对应物对共轭物的靶向部分都有用。本发明包括合成这些共轭物所需的化合物、载体-药物共轭物的适当药物组成以及它们的使用方法。
• Linkers useful for the synthesis of conjugates of methyltrithio
  申请人：American Cyanamid Company

  公开号：US05767285A1

  公开（公告）日：1998-06-16

  This invention describes carrier-drug conjugates prepared from disulfide analogs of the calicheamicin family of potent antitumor antibiotics and their derivatives, as well as similar analogs from related antitumor antibiotics such as the esperamicins. The carrier can be an antibody, growth factor, or steroid which targets an undesired population of cells, such as those of a tumor. Whole protein carriers as well as their antigen-recognizing fragments and their chemically or genetically manipulated counterparts are useful for the targeting portion of the conjugates. This invention includes compounds required for the synthesis of these conjugates, appropriate pharmaceutical compositions of the carrier-drug conjugates, and their method of use.

  本发明描述了由强效抗肿瘤抗生素calicheamicin家族的二硫键类似物及其衍生物以及类似的esperamicins的类似物制备的载体-药物共轭物，载体可以是抗体、生长因子或类固醇，其针对不需要的细胞群体，例如肿瘤细胞。整个蛋白质载体以及它们的抗原识别片段和它们的化学或基因操作的对应物对于共轭物的靶向部分是有用的。本发明包括用于这些共轭物的合成所需的化合物，载体-药物共轭物的适当药物组成以及它们的使用方法。
• Process for preparing conjugates of methyltrithio antitumor agents
  申请人：American Cyanamid Company

  公开号：US05877296A1

  公开（公告）日：1999-03-02

  This invention describes carrier-drug conjugates prepared from disulfide analogs of the calicheamicin family of potent antitumor antibiotics and their derivatives, as well as similar analogs from related antitumor antibiotics such as the esperamicins. The carrier can be an antibody, growth factor, or steroid which targets an undesired population of cells, such as those of a tumor. Whole protein carriers as well as their antigen-recognizing fragments and their chemically or genetically manipulated counterparts are useful for the targeting portion of the conjugates. This invention includes compounds required for the synthesis of these conjugates, appropriate pharmaceutical compositions of the carrier-drug conjugates, and their method of use.

  本发明描述了从卡利切阿霉素家族的二硫化物类似物及其衍生物以及类似的抗肿瘤抗生素如埃斯佩拉霉素中制备的载体-药物结合物，载体可以是抗体、生长因子或类固醇，其靶向不需要的细胞群体，例如肿瘤细胞。整个蛋白质载体以及其抗原识别片段以及其化学或基因操纵的对应物对于结合物的靶向部分是有用的。本发明包括合成这些结合物所需的化合物，载体-药物结合物的适当药物组成以及它们的使用方法。
• Rational design, synthesis and structure–activity relationships of 4-alkoxy- and 4-acyloxy-phenylethylenethiosemicarbazone analogues as novel tyrosinase inhibitors
  作者：Ao You、Jie Zhou、Senchuan Song、Guoxun Zhu、Huacan Song、Wei Yi

  DOI：10.1016/j.bmc.2015.01.024

  日期：2015.3

  In continuing our program aimed to search for potent compounds as highly efficient tyrosinase inhibitors, here a series of novel 4-alkoxy- and 4-acyloxy-phenylethylenethiosemicarbazone analogues were designed, synthesized and their biological activities on mushroom tyrosinase were evaluated. Notably, most of compounds displayed remarkable tyrosinase inhibitory activities with IC50 value of lower than 1.0 mu M. Furthermore, the structure-activity relationships (SARs) were discussed and the inhibition mechanism and the inhibitory kinetics of selected compounds 7k and 8d were also investigated. Taken together, these results suggested that such compounds could serve as the promising candidates for the treatment of tyrosinase-related disorders and further development of such compounds might be of great interest. (C) 2015 Published by Elsevier Ltd.